Status:
UNKNOWN
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
Lead Sponsor:
Amsterdam UMC, location VUmc
Collaborating Sponsors:
Radboud University Medical Center
Conditions:
Invasive Candidiasis
Candidemia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine the pharmacokinetics of anidulafungin in intensive care patients.
Detailed Description
Not a lot is known about the pharmacokinetic profile of anidulafungin in IC-patients. IC-patients are at high(er) risk for getting a systemic mould/yeast infection. Anidulafungin is a safe echinocandi...
Eligibility Criteria
Inclusion
- Patient is admitted to the intensive care unit
- Patient has a central (venous) infusion line
- Patient is at least 18 years old
- Patient receives treatment with anidulafungin
- that is initiated on the ICU or
- that is continued on the ICU and the patient has had no more than 2 days of treatment with anidulafungin
Exclusion
- Documented history of sensitivity to medicinal products or excipients similar to those found in the anidulafungin preparation
- Patient receives treatment with anidulafungin that is continued on the ICU and the patient has had 3 or more days of treatment with anidulafungin
- A woman that is pregnant, wanting to become pregnant or nursing an infant
- \< 48 hours (expected) treatment with anidulafungin on the ICU ward
- Has previously participated in this trial.
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01438216
Start Date
September 1 2011
End Date
March 1 2012
Last Update
September 22 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Center
Nijmegen, Gelderland, Netherlands, 6525 GA
2
VU University Medical Center
Amsterdam, North Holland, Netherlands, 1081 HV